Franklin Resources Inc. Boosts Holdings in AnaptysBio Inc (ANAB)

Franklin Resources Inc. boosted its holdings in shares of AnaptysBio Inc (NASDAQ:ANAB) by 16.6% during the fourth quarter, Holdings Channel reports. The fund owned 325,600 shares of the biotechnology company’s stock after purchasing an additional 46,400 shares during the quarter. Franklin Resources Inc.’s holdings in AnaptysBio were worth $32,794,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wells Fargo & Company MN grew its holdings in AnaptysBio by 92.3% during the 3rd quarter. Wells Fargo & Company MN now owns 7,326 shares of the biotechnology company’s stock worth $256,000 after acquiring an additional 3,516 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in AnaptysBio by 210.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after acquiring an additional 124,219 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in AnaptysBio by 69.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 32,846 shares of the biotechnology company’s stock worth $1,148,000 after acquiring an additional 13,444 shares during the last quarter. American International Group Inc. grew its holdings in AnaptysBio by 140.5% during the 3rd quarter. American International Group Inc. now owns 7,972 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 4,657 shares during the last quarter. Finally, Brown Advisory Inc. bought a new stake in AnaptysBio during the 4th quarter worth approximately $6,549,000. 99.25% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

ANAB has been the topic of a number of research reports. SunTrust Banks boosted their target price on shares of AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Robert W. Baird reissued a “buy” rating and set a $144.00 target price (up from $81.00) on shares of AnaptysBio in a report on Friday, January 19th. Royal Bank of Canada boosted their target price on shares of AnaptysBio to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 2nd. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, ValuEngine raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Buy” and a consensus price target of $129.67.

ANAB stock opened at $113.73 on Wednesday. The stock has a market cap of $2,605.28, a P/E ratio of -69.77 and a beta of 1.94. AnaptysBio Inc has a 1 year low of $18.15 and a 1 year high of $134.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.93 and a quick ratio of 17.93.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.12. The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $0.89 million. The business’s quarterly revenue was up 9.1% on a year-over-year basis. equities research analysts forecast that AnaptysBio Inc will post -2.3 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3285019/franklin-resources-inc-boosts-holdings-in-anaptysbio-inc-anab.html.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Robert Half International  Trading 0.3% Higher  on Analyst Upgrade
Robert Half International Trading 0.3% Higher on Analyst Upgrade
Texas Instruments  Shares Gap Up  on Analyst Upgrade
Texas Instruments Shares Gap Up on Analyst Upgrade
Samuel Adams  Hits New 1-Year High and Low After Strong Earnings
Samuel Adams Hits New 1-Year High and Low After Strong Earnings
Peoples Financial Services  Announces  Earnings Results
Peoples Financial Services Announces Earnings Results
Tupperware Brands  Issues Q2 Earnings Guidance
Tupperware Brands Issues Q2 Earnings Guidance
SEACOR  Posts  Earnings Results, Beats Expectations By $0.04 EPS
SEACOR Posts Earnings Results, Beats Expectations By $0.04 EPS


© 2006-2018 Ticker Report. Google+.